Our perspectives
in one place
Topic
Selected filters
Clear
News
See allUN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)
IFPMA statement at the UN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR) in New York on 9 June. We share the same objective: a world better prepared to prevent, prepare for, detect, and respond to pandemics. Industry is a core part of that system, engaging in strengthening the health of populations, developing vaccines...
Read morePharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreak
The latest Ebola Bundibugyo outbreak in Democratic Republic of Congo, Uganda, and neighbouring countries is deeply concerning. Pharmaceutical and biotech companies are working with global partners in a coordinated response. Accelerating the response As the scientific, humanitarian, and global health response accelerates to contain the outbreak, pharmaceutical companies remain central to these efforts. While no...
Read more79th World Health Assembly: Constituency statement on the follow-up to the Political Declaration on non-communicable diseases
On 21 May 2026, the International Federation on Ageing delivered a joint constituency statement on the follow-up to the Political Declaration on non-communicable diseases (NCDs) at the 79th session of the World Health Assembly. We urge WHO and Member States to ensure that implementation of the Political Declaration on the prevention and control of NCDs...
Read moreGlobal biopharmaceutical leaders meet Japanese Prime Minister to reinforce action needed to retain Japan’s leadership in life‑sciences
28 MAY 2026, TOKYO – A delegation of over 20 global pharmaceutical leaders from top American, Japanese and European biopharmaceutical companies met this week with Prime Minister Sanae Takaichi to reinforce the action needed for Japan to grow its leadership in life sciences. Pharmaceutical industry amongst highest R&D intensive sectors in Japan Over the past...
Read more79th World Health Assembly (WHA79): Draft updated global action plan on antimicrobial resistance
On 23 May 2026, IFPMA delivered a statement on the draft updated Global Action Plan on antimicrobial resistance at the 79th session of the World Health Assembly in Geneva. We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress to date and...
Read more79th session of the World Health Assembly (WHA79): Harmonization of regulatory approaches, governance, and standards for data, digital health, and artificial intelligence in the health sector
On 23 May 2026, IFPMA delivered a statement on the harmonization of regulatory approaches, governance, and standards for data, digital health, and artificial intelligence in the health sector at the 79th session of the World Health Assembly in Geneva. Noting the previous work on digital health transformation, AI, and data governance, and the first WHO...
Read morePublications
See allIFPMA Note for Guidance on educational and scientific events (2026 update)
Collaborations between healthcare professionals (HCPs) and the pharmaceutical industry are essential and ensure that patients have access to the medicines they need and that healthcare professionals have up-to-date comprehensive information about the diseases they treat and the medicines they prescribe.
Read more
Investing in productive economies and resilient societies: The vital role of adult immunization
As populations age and rates of NCDs rise across all demographics, adult immunization represents a high-impact and cost-effective investment in economic growth and societal resilience. This two-pager outlines four policy recommendations to ensure adult immunization is prioritized within national budgets.
Read more
Advancing GMP inspection reliance – from pilots to practice
Around the world, National Regulatory Agencies (NRAs) face mounting pressure to ensure access to and availability of high-quality medicinal products while confronted with an increasing number of sites to inspect, a demand driven by a need to strengthen supply resilience and manage limited inspection resources. This position paper represents the views of the research-based biopharmaceutical...
Read more
Expert insights
See all
Innovative medicines as drivers of economic security – A strategic imperative for G7 economies
Read more
Foundations of competitiveness and growth start with strong healthcare systems and healthy populations
Read more
A better global health architecture delivers both innovation and access
Read moreResources
See allStreamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more